- JP-listed companies
- Cash flow
(504A) Cash flow
Market cap
¥38.7B
P/E ratio
Innovacell develops cell therapy treatments for incontinence using patients' own muscle cells to restore damaged muscle function. The company has three products in clinical trials with potential first-mover advantage in this specialized field.
| 2023/12 | 2024/12 | 2025/12 | |
| Depreciation & amortization | 53 | 54 | 64 |
| Cash from operations | -1,407 | -1,298 | -1,995 |
| Capital expenditures | -61 | -12 | -43 |
| Cash from investing | 1,003 | -11 | -54 |
| Repayments of term debt | -315 | -50 | -51 |
| Cash from financing | 511 | 2,143 | 4,090 |